Business Context and Reporting Period
This Form 8-K reports on events occurring on June 14, 2024, specifically the 2024 Annual Meeting of Stockholders for Cartesian Therapeutics, Inc. (Nasdaq: RNAC). The filing details the outcomes of shareholder votes regarding director elections, executive compensation, equity incentive plans, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder actions. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial statements.
Material Changes and Voting Results
At the Annual Meeting, approximately 77.29% of outstanding common stock (13,755,429 shares) was present or represented by proxy. All four proposals presented to shareholders were approved:
- Proposal 1 (Director Elections): Two Class II directors were elected to serve until the 2027 Annual Meeting:
- Carrie S. Cox: 11,829,626 votes FOR; 316,083 votes WITHHELD.
- Murat Kalayoglu, M.D., Ph.D.: 12,106,239 votes FOR; 39,470 votes WITHHELD.
- Proposal 2 (Executive Compensation): Shareholders approved, on a non-binding advisory basis, the compensation of named executive officers with 11,684,828 votes FOR and 443,703 votes AGAINST.
- Proposal 3 (Incentive Plan): The Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan was approved with 11,273,065 votes FOR and 856,549 votes AGAINST.
- Proposal 4 (Auditor Ratification): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2024, was ratified with 13,537,162 votes FOR and 212,286 votes AGAINST.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future business guidance, financial outlook, or specific risk factors. The document focuses strictly on the procedural results of the shareholder vote. The approval of the Amended and Restated 2016 Incentive Award Plan indicates the company's intent to continue utilizing equity-based compensation, though specific terms are referenced in the Proxy Statement filed on April 26, 2024.
Key Facts for Investor Verification
- Verify the specific terms and share reserve limits of the newly approved Amended and Restated 2016 Incentive Award Plan in the April 26, 2024 Proxy Statement.
- Confirm the tenure of the newly elected directors, Carrie S. Cox and Murat Kalayoglu, which extends through the 2027 Annual Meeting.
- Note that Ernst & Young LLP has been ratified as the auditor for the fiscal year ending December 31, 2024.
- Review the company's latest periodic reports (10-K/10-Q) for financial health metrics, as this 8-K contains no financial data.